Cory Renauer
Value, research analyst, biotech, small-cap

MacroGenics Climbing The MAB Ladder With A Safety Net

In the biotech space it's actually difficult to find young companies that don't look like multi-bagger opportunities through the eyes of young investors. Sadly, few of us look at the industry through young eyes for very long. With less than 10% of pre-clinical programs reaching commercial stages, investing in a startup biotech with intentions to develop, and then market its own compounds is riskier than jumping off a building in a homemade Batman suit. You don't need to suffer too many disasters before age sets in, and you begin looking for companies with some sort of safety net.

Luckily, there is a hybrid option for wide eyed biotech investors yearning for the potential of a huge payoff, without the threat...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details